S. Finotto

Immunology · 2000–2011

A researcher in the Science corpus: 5 papers; trusts 1 researcher and is trusted by 1 researcher here, as inferred from the citation graph.

Subfields

Whom S. Finotto trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

  1. T. Kishimoto
  2. Paul R. Mangan

Who trusts S. Finotto overall

  1. Markus F. Neurath
  2. Ming O. Li
  3. P. Barnes
  4. Q. Guan
  5. R. Flavell
  6. Jinfang Zhu

Papers from S. Finotto's perspective

Ordered by how strongly the researchers S. Finotto trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells (Nature)
  2. Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial. (Arthritis & Rheumatism)
  3. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
  4. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo (Nature Medicine)
  5. Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF beta receptor for degradation. (Molecules and Cells)
  6. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease (Nature)
  7. IL-6 and STAT3 are required for survival of intestinal epithelial cells and development of colitis associated cancer (Cancer Cell)
  8. Transforming growth factor-beta induces development of the T(H)17 lineage. (Nature)
  9. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease (Nature)
  10. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. (Immunity)

Their papers